-
Mashup Score: 0Greater Pre-Existing Radiographic Damage in Psoriatic Arthritis May Reduce Chance of Full Inhibition With Secukinumab - 1 year(s) ago
Secukinumab therapy was associated with inhibition of joint tenderness and swelling, but high baseline radiographic damage was associated with reduced likelihood of full inhibition.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
SUNSHINE and SUNRISE trial data will be submitted to the FDA as part of Novartis’ Biologics License Application (BLA) for secukinumab in hidradenitis suppurativa.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#Secukinumab Shows Rapid, Sustained Improvement of #HidradenitisSuppurativa. https://t.co/2t1jiUA4rV https://t.co/b5cqd2lQCn
-
-
Mashup Score: 1Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study - 2 year(s) ago
Objective To evaluate secukinumab (SEC) 300 mg and 150 mg vs placebo in a United States–only population of biologic-naïve patients with psoriatic arthritis (PsA). Methods CHOICE was a double-blind, randomized controlled trial conducted in the US. Biologic-naïve patients with PsA and psoriasis (PsO) were randomized 2:2:1 to SEC 300 mg (n = 103), SEC 150 mg (n = 103), or placebo (n = 52). The…
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet-
Open Access Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study 📰 https://t.co/RV2b1ToPup #psoriaticarthritis #secukinumab https://t.co/EWEVT4PHsh
-
-
Mashup Score: 0
New 21-month data from the SUSTAIN trial found that patients with no history of biologic therapies responded well to secukinumab.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
New 21-month data from the SUSTAIN study found that the biologic #secukinumab demonstrated high drug survival and sustained efficacy in both biologic-naïve and biologic-experienced patients with chronic plaque #psoriasis. https://t.co/CnLlG7Sg3k
-
-
Mashup Score: 2Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry - 2 year(s) ago
Objective. To evaluate clinical and patient-reported outcomes (PROs) at 6 months after secukinumab initiation in US patients with psoriatic arthritis (PsA). Methods. Patients with PsA in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry who initiated secukinumab between April 1, 2017, and December 2, 2019, and maintained secukinumab at their 6-month follow-up visit were included….
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet-
Open Access Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry 📰 https://t.co/OLvW4oIcTt #psoriaticarthritis #spondyloarthritis #secukinumab https://t.co/DIQYIOQZVS
-
-
Mashup Score: 0
The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.
Source: Contemporary PediatricsCategories: Latest Headlines, PediatricsTweet-
#Secukinumab receives expanded approvals in EU for pediatric #arthritic conditions. https://t.co/Yvd67IUKth https://t.co/FNMt22pL9K
-
-
Mashup Score: 0
The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
The European Commission approved #secukinumab, either alone or in combination with methotrexate, in juvenile idiopathic #arthritis enthesitis-related arthritis and juvenile #PsoriaticArthritis. https://t.co/HVGBXyFxTf
-
-
Mashup Score: 1
The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
The approvals were based on results from the JUNIPERA trial, which showed #secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA. https://t.co/anTvpBbeBG #JuvenileArthritis
-
-
Mashup Score: 0
Real-world patients with psoriatic arthritis who receive secukinumab for 6 months maintain consistent proportions of minimal disease activity and demonstrate improved patient-reported outcomes, according to data.“Secukinumab, a fully humanized monoclonal antibody that selectively inhibits interleukin (IL)-17A is approved for the treatment of PsA and improves all PsA manifestations in the
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
ICYMI: "Few studies in the United States have evaluated the effectiveness of #secukinumab in patients with #PsA in real-world settings," Philip Mease, MD, and colleagues wrote. https://t.co/IkbI29y2zX
-
-
Mashup Score: 1
Real-world patients with psoriatic arthritis who receive secukinumab for 6 months maintain consistent proportions of minimal disease activity and demonstrate improved patient-reported outcomes, according to data.“Secukinumab, a fully humanized monoclonal antibody that selectively inhibits interleukin (IL)-17A is approved for the treatment of PsA and improves all PsA manifestations in the
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Real-world patients with psoriatic #arthritis who receive #secukinumab for 6 months maintain consistent proportions of minimal disease activity and demonstrate improved patient-reported outcomes #RheumTwitter https://t.co/OmTSOdxR9U
-
Real-world patients with psoriatic #arthritis who receive #secukinumab for 6 months maintain consistent proportions of minimal disease activity and demonstrate improved patient-reported outcomes #RheumTwitter https://t.co/IkbI29y2zX
-
#Secukinumab therapy was associated with inhibition of joint tenderness/swelling, but high baseline radiographic damage was associated with reduced likelihood of full inhibition. https://t.co/xKCHTHIzbE #PsoriaticArthritis